Advisor Group Holdings, Inc. Oncternal Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.28 - $0.64 $1,008 - $2,304	-3,600 Reduced 28.92%	8,850 $4,000
Q3 2023 Nov 13, 2023	BUY	$0.29 - $0.48 $286 - $474	988 Added 8.62%	12,450 $3,000
Q2 2023 Aug 10, 2023	SELL	$0.28 - $0.79 $2,322 - $6,553	-8,295 Reduced 41.99%	11,462 $3,000
Q1 2023 May 12, 2023	BUY	$0.63 - $1.3 $103 - $213	164 Added 0.84%	19,757 $15,000
Q4 2022 Feb 10, 2023	SELL	$0.86 - $22.2 $849 - $21,933	-988 Reduced 4.8%	19,593 $19,000
Q3 2022 Nov 14, 2022	SELL	$0.83 - $17.8 $1,660 - $35,600	-2,000 Reduced 8.86%	20,581 $19,000
Q2 2022 Aug 10, 2022	SELL	$0.7 - $1.56 $700 - $1,560	-1,000 Reduced 4.24%	22,581 $25,000
Q1 2022 May 04, 2022	SELL	$1.37 - $2.43 $6,165 - $10,935	-4,500 Reduced 16.03%	23,581 $32,000
Q3 2021 Nov 05, 2021	BUY	$3.37 - $4.76 $8,866 - $12,523	2,631 Added 10.34%	28,081 $117,000
Q2 2021 Aug 02, 2021	BUY	$4.75 - $9.39 $86,212 - $170,428	18,150 Added 248.63%	25,450 $121,000
Q1 2021 May 13, 2021	BUY	$4.59 - $9.04 $10,557 - $20,791	2,300 Added 46.0%	7,300 $61,000
Q4 2020 Feb 10, 2021	BUY	$1.51 - $6.3 $7,550 - $31,500	5,000 New	5,000 $25,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.